ALLOGENE THERAPEUTICS INC (ALLO)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ALLO
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALLO | 63 | [] | ["Audit","Compensation"] | 2026 |
Biography sourced from the proxy statement filing.
John DeYoung has served as a member of our Board since April 2018. Mr. DeYoung serves as a member of the Compensation Committee and the International and Business Development Oversight Committee. Mr. DeYoung is Vice President of Worldwide Business Development for Pfizer s Oncology Business Unit. He is a member of Pfizer s Oncology Leadership Team and its Worldwide Business Development Leadership Team. Mr. DeYoung joined Pfizer in 1991 and has held leadership positions in Finance, Marketing, Commercial Development and Business Development. Mr. DeYoung received his bachelor s degree in business from Michigan State University in 1985 and his MBA from the University of Chicago in 1990. Skills and Qualifications : Our Nominating and Corporate Governance Committee and Board of Directors believe Mr. DeYoung s expertise and experience in the life sciences and his financial background provide him with the qualifications and skills to serve on our Board of Directors.